![]() |
|
|
Vol. 290, Issue 2, 678-686, August 1999
Laboratory on the Biology of Addictive Diseases, Rockefeller
University, New York, New York
The effects of i.v. dynorphin A(1-17) and its main nonopioid
biotransformation fragment, dynorphin A(2-17), were compared in rhesus
monkeys with those of the selective
-opioid agonist, U69,593, in
assays of operant behavior, thermal antinociception, and neuroendocrine
function (prolactin release). Dynorphin A(1-17) (0.1-3.2 mg/kg i.v.)
and U69,593 (0.001-0.032 mg/kg s.c.) decreased rates of
schedule-controlled (fixed ratio 20) food-reinforced responding,
whereas dynorphin A(2-17) (1-3.2 mg/kg i.v.) was ineffective. Pretreatment studies with the opioid antagonist quadazocine (0.32 mg/kg
s.c.) revealed that the operant effects of dynorphin A(1-17) were not
mediated by
- or µ-opioid receptors. A different profile was
observed in the warm water tail withdrawal assay of thermal antinociception, where both dynorphin A(1-17) and A(2-17) (0.032-3.2 mg/kg i.v., n = 4) were modestly effective in
50°C water, and both were ineffective in 55°C water. By comparison,
U69,593 (0.032-0.18 mg/kg s.c.) was maximally effective in 50°C
water and partially effective in 55°C.
-opioid agonists
increase serum levels of prolactin in animals and humans.
Dynorphin A(1-17) (ED50 = 0.0011 mg/kg i.v.), similar
to U69,593 (ED50 = 0.0030 mg/kg i.v.), was very potent
in increasing serum prolactin levels in follicular phase female rhesus
monkeys, whereas dynorphin A(2-17) (0.32 mg/kg i.v.) was ineffective.
The effects of dynorphin A(1-17) and U69,593 on serum prolactin were
both antagonized by quadazocine (0.32 mg/kg s.c.) in a surmountable
manner, consistent with opioid receptor mediation. The present studies
show that serum prolactin levels are a sensitive quantitative endpoint
to study the systemic effects of the endogenous opioid peptide,
dynorphin A(1-17), in primates.
This article has been cited by other articles:
![]() |
E. R. Butelman, J. W. Ball, T. J. Harris, and M. J. Kreek Topical Capsaicin-Induced Allodynia in Unanesthetized Primates: Pharmacological Modulation J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1106 - 1114. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bart, L. Borg, J. H. Schluger, M. Green, A. Ho, and M. J. Kreek Suppressed Prolactin Response to Dynorphin A1-13 in Methadone-Maintained Versus Control Subjects J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 581 - 587. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Butelman, M. C. H. Ko, J. R. Traynor, J. A. Vivian, M.-J. Kreek, and J. H. Woods GR89,696: A Potent kappa -Opioid Agonist with Subtype Selectivity in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1049 - 1059. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. H. Ko, M. D. Johnson, E. R. Butelman, K. J. Willmont, H. I. Mosberg, and J. H. Woods Intracisternal Nor-Binaltorphimine Distinguishes Central and Peripheral kappa -Opioid Antinociception in Rhesus Monkeys J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1113 - 1120. [Abstract] [Full Text] |
||||